FCM
GBT

Farallon Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Farallon Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-450,000
Closed -$30.6M – 317
2022
Q3 		$30.6M Buy
+450,000
New +$24.8M 0.17% 87
2022
Q2 		– Sell
-169,458
Closed -$5.87M – 329
2022
Q1 		$5.87M Buy
169,458
+83,004
+96% +$2.48M 0.03% 178
2021
Q4 		$2.53M Buy
+86,454
New +$2.68M 0.01% 205
2020
Q4 		– Sell
-600,000
Closed -$33.1M – 157
2020
Q3 		$33.1M Buy
+600,000
New +$38.1M 0.23% 75
2020
Q1 		– Sell
-750,000
Closed -$59.6M – 122
2019
Q4 		$59.6M Sell
750,000
-862,069
-53% -$51.1M 0.4% 48
2019
Q3 		$78.2M Buy
1,612,069
+487,069
+43% +$25.4M 0.59% 39
2019
Q2 		$59.2M Sell
1,125,000
-375,000
-25% -$21.6M 0.38% 53
2019
Q1 		$79.4M Buy
1,500,000
+50,000
+3% +$2.46M 0.6% 43
2018
Q4 		$59.5M Buy
1,450,000
+80,000
+6% +$3M 0.44% 44
2018
Q3 		$52.1M Buy
1,370,000
+185,000
+16% +$8.19M 0.31% 50
2018
Q2 		$53.6M Buy
+1,185,000
New +$54M 0.33% 50
2018
Q1 		– Sell
-340,000
Closed -$13.4M – 102
2017
Q4 		$13.4M Buy
+340,000
New +$12.7M 0.11% 62

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's GBT Position: Q4 2022 in Review

Farallon Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 450,000 shares — an estimated $30.6M sold.

Farallon Capital Management first reported a position in GBT in Q4 2017 and held it in 12 quarters. The position peaked at $79.4M in Q1 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Farallon Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Farallon Capital Management sold 450,000 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $30.6M.
  • Farallon Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 12 quarters.
  • Farallon Capital Management's Global Blood Therapeutics, Inc. position peaked at $79.4M in Q1 2019.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Farallon Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.